A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Prior treatment

• Exacerbation of underlying lung disease within 28 days prior to randomization.
• Initiation of pulmonary rehabilitation within 28 days prior to randomization.
• Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
• Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.
  • Note: Other inclusion and exclusion criteria may apply.

Other illness

• Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).

Other

• History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.

• Participants willing and able to provide informed consent
• Participants on inhaled treprostinil
• Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:
  • Idiopathic interstitial pneumonia (IIP)
  • Chronic hypersensitivity pneumonitis
  • ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
• Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
• Ability to perform 6MWD ≥100 meters.